Suppr超能文献

原卟啉 IX 诱导的光毒性:机制与治疗。

Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics.

机构信息

Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Porphyria Laboratory and Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555, USA.

出版信息

Pharmacol Ther. 2023 Aug;248:108487. doi: 10.1016/j.pharmthera.2023.108487. Epub 2023 Jun 29.

Abstract

Protoporphyrin IX (PPIX) is an intermediate in the heme biosynthesis pathway. Abnormal accumulation of PPIX due to certain pathological conditions such as erythropoietic protoporphyria and X-linked protoporphyria causes painful phototoxic reactions of the skin, which can significantly impact daily life. Endothelial cells in the skin have been proposed as the primary target for PPIX-induced phototoxicity through light-triggered generation of reactive oxygen species. Current approaches for the management of PPIX-induced phototoxicity include opaque clothing, sunscreens, phototherapy, blood therapy, antioxidants, bone marrow transplantation, and drugs that increase skin pigmentation. In this review, we discuss the present understanding of PPIX-induced phototoxicity including PPIX production and disposition, conditions that lead to PPIX accumulation, symptoms and individual differences, mechanisms, and therapeutics.

摘要

原卟啉 IX(PPIX)是血红素生物合成途径中的中间产物。由于某些病理情况,如红细胞生成性原卟啉症和 X 连锁原卟啉症,导致 PPIX 的异常积累,从而引起皮肤疼痛性光毒性反应,这会显著影响日常生活。皮肤中的内皮细胞已被提出为 PPIX 诱导的光毒性的主要靶标,通过光触发产生活性氧。目前管理 PPIX 诱导的光毒性的方法包括不透明衣物、防晒霜、光疗、血液疗法、抗氧化剂、骨髓移植和增加皮肤色素沉着的药物。在这篇综述中,我们讨论了目前对 PPIX 诱导的光毒性的理解,包括 PPIX 的产生和分布、导致 PPIX 积累的情况、症状和个体差异、机制和治疗方法。

相似文献

1
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics.
Pharmacol Ther. 2023 Aug;248:108487. doi: 10.1016/j.pharmthera.2023.108487. Epub 2023 Jun 29.
2
The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
Sci Adv. 2019 Sep 18;5(9):eaaw6127. doi: 10.1126/sciadv.aaw6127. eCollection 2019 Sep.
5
6
Erythropoietic protoporphyrias: updates and advances.
Trends Mol Med. 2024 Sep;30(9):863-874. doi: 10.1016/j.molmed.2024.05.006. Epub 2024 Jun 17.
7
Inactivation of protoporphyrin IX in erythrocytes in patients with erythropoietic protoporphyria: A new treatment modality.
Photodiagnosis Photodyn Ther. 2020 Mar;29:101582. doi: 10.1016/j.pdpdt.2019.101582. Epub 2019 Dec 3.
8
Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria.
Cell Chem Biol. 2021 Aug 19;28(8):1221-1234.e6. doi: 10.1016/j.chembiol.2021.02.021. Epub 2021 Mar 22.
9
Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
Mol Genet Metab. 2019 Nov;128(3):298-303. doi: 10.1016/j.ymgme.2019.01.020. Epub 2019 Jan 24.

引用本文的文献

4
Inhibition of ABCG2 prevents phototoxicity in a mouse model of erythropoietic protoporphyria.
Nat Commun. 2024 Dec 4;15(1):10557. doi: 10.1038/s41467-024-54969-6.
5
Heme (dys)homeostasis and liver disease.
Front Physiol. 2024 Jul 29;15:1436897. doi: 10.3389/fphys.2024.1436897. eCollection 2024.
6
Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management.
Liver Int. 2025 Jan;45(1):e16027. doi: 10.1111/liv.16027. Epub 2024 Jul 16.
8
Photochemical and biological dual-effects enhance the inhibition of photosensitizers for tumour growth.
Chem Sci. 2024 Apr 25;15(20):7757-7766. doi: 10.1039/d4sc00874j. eCollection 2024 May 22.
9
Iron metabolism: backfire of cancer cell stemness and therapeutic modalities.
Cancer Cell Int. 2024 May 4;24(1):157. doi: 10.1186/s12935-024-03329-x.
10
Roles of the ABCG2 Transporter in Protoporphyrin IX Distribution and Toxicity.
Drug Metab Dispos. 2024 Oct 16;52(11):1201-1207. doi: 10.1124/dmd.123.001582.

本文引用的文献

2
Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist.
Eur J Clin Pharmacol. 2023 Jun;79(6):801-813. doi: 10.1007/s00228-023-03476-6. Epub 2023 Apr 15.
3
Dersimelagon in Erythropoietic Protoporphyrias.
N Engl J Med. 2023 Apr 13;388(15):1376-1385. doi: 10.1056/NEJMoa2208754.
4
How I treat erythropoietic protoporphyria and X-linked protoporphyria.
Blood. 2023 Jun 15;141(24):2921-2931. doi: 10.1182/blood.2022018688.
5
The Oral Bioavailability and Effect of Various Gastric Conditions on the Pharmacokinetics of Dersimelagon in Healthy Adult Volunteers.
Clin Pharmacol Drug Dev. 2023 May;12(5):493-501. doi: 10.1002/cpdd.1235. Epub 2023 Feb 25.
7
Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria.
J Am Acad Dermatol. 2023 Dec;89(6):1227-1237. doi: 10.1016/j.jaad.2022.08.036. Epub 2022 Aug 27.
8
Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist.
Skin Health Dis. 2021 Nov 29;2(1):e78. doi: 10.1002/ski2.78. eCollection 2022 Mar.
9
Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.
Sci Rep. 2022 Apr 12;12(1):6100. doi: 10.1038/s41598-022-10089-z.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验